---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-066613"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:21:00.135384+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics Provides Q2 2024 Corporate Update and Financial Results

## Summary
- Collaborated with Abbott to advance tecarfarin for LVAD patients using HeartMate 3 device.
- Received FDA Orphan Drug Designation in April 2024 for preventing blood clots and strokes in LVAD patients.
- Q2 2024 operating expenses (ex-non-cash) totaled $2.3 million; cash used in operations was $1.5 million.
- Cash balance as of June 30, 2024 was $5.0 million.
- CEO Quang Pham highlighted progress on pivotal trial and LVAD study protocol development.

## SEC filing metadata
- accession: 0001213900-24-066613
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390024066613/0001213900-24-066613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390024066613/ea021083501-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-066613
- JSON: https://secwatch.observer/filing/0001213900-24-066613.json
- Plain text: https://secwatch.observer/filing/0001213900-24-066613.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.